EMREX Performance — JPMorgan Emerging Markets Research Enhanced Equity Fund, Class I
Data updated: 2026-09-28
EMREX returned +19.12% year to date and +37.13% over one year to Jul 2026. Annualised returns are +18.46% over 3 years and +7.18% over 5 years. The fund beat its Emerging Markets Equity category average: $100 invested three years ago grew to $166, against $164 for the category, and to $137 over one year, against $134. Volatility over the past three years was 16.24% a year. In the 12 months to Jul 2026 the fund lost a net $759.3M, and assets reached $2.05B.
EMREX Growth of $100
What $100 invested in JPMorgan Emerging Markets Research Enhanced Equity Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Emerging Markets Equity category average over the same months.
| Period | EMREX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $137 | $134 |
| 3 years (Aug 2023 – Jul 2026) | $166 | $164 |
| 5 years (Aug 2021 – Jul 2026) | $141 | $143 |
| Since data start (Aug 2019 – Jul 2026) | $184 | $188 |
EMREX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +19.12% |
| 1 year | +37.13% |
| 3 years (annualised) | +18.46% |
| 5 years (annualised) | +7.18% |
EMREX Annual Returns
Calendar-year total returns of JPMorgan Emerging Markets Research Enhanced Equity Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +19.12% |
| 2025 | +35.07% |
| 2024 | +6.36% |
| 2023 | +8.79% |
| 2022 | −21.47% |
| 2021 | −3.38% |
| 2020 | +18.42% |
| 2019 (Aug–Dec) | +9.90% |
EMREX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.6% | +6.4% | −9.9% | +12.6% | +7.3% | +0.5% | −5.9% | — | — | — | — | — |
| 2025 | +2.3% | +0.8% | +1.6% | +0.1% | +4.0% | +6.6% | +1.0% | +2.6% | +7.0% | +3.6% | −1.7% | +2.9% |
| 2024 | −4.4% | +4.4% | +2.4% | −0.1% | +1.4% | +3.8% | +0.5% | +0.6% | +5.3% | −4.0% | −2.3% | −1.0% |
| 2023 | +9.5% | −6.9% | +2.9% | −1.2% | −2.5% | +4.4% | +6.2% | −6.8% | −2.7% | −3.6% | +7.1% | +3.7% |
| 2022 | +0.2% | −5.9% | −2.8% | −5.8% | +1.3% | −6.2% | −1.3% | −0.7% | −11.5% | −2.6% | +16.6% | −2.8% |
| 2021 | +3.5% | +1.0% | −1.1% | +1.2% | +1.5% | +1.3% | −7.2% | +2.0% | −3.8% | +1.2% | −4.6% | +2.2% |
| 2020 | −5.4% | −3.8% | −16.7% | +8.0% | +1.8% | +6.8% | +8.0% | +2.9% | −1.2% | +2.7% | +9.7% | +7.6% |
| 2019 | — | — | — | — | — | — | — | −3.8% | +2.3% | +3.6% | +0.3% | +7.4% |
EMREX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 16.24%
- 3-year Sharpe ratio: 0.86 (vs 4.5% risk-free rate)
- Best month: +12.63% (Apr 2026)
- Worst month: −9.91% (Mar 2026)
EMREX Fund Flows
Monthly money in and out of JPMorgan Emerging Markets Research Enhanced Equity Fund, from SEC Form N-PORT.
- 12-month net flow: −$759.3M
- 12-month gross sales (incl. reinvestments): $469.6M
- Sales ÷ redemptions: 0.38×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $27.9M | $14.5M | $13.5M |
| Jun 2026 | $11.4M | $89.7M | −$78.3M |
| May 2026 | $31.7M | $136.0M | −$104.3M |
| Apr 2026 | $138.7M | $64.2M | $74.4M |
| Mar 2026 | $43.5M | $38.6M | $4.9M |
| Feb 2026 | $32.9M | $110.2M | −$77.3M |
| Jan 2026 | $4.2M | $190.2M | −$186.0M |
| Dec 2025 | $115.7M | $10.6M | $105.1M |
| Nov 2025 | $6.6M | $45.2M | −$38.5M |
| Oct 2025 | $5.7M | $105.5M | −$99.8M |
| Sep 2025 | $35.0M | $37.8M | −$2.8M |
| Aug 2025 | $16.3M | $386.4M | −$370.2M |
EMREX Assets Under Management
Net assets of JPMorgan Emerging Markets Research Enhanced Equity Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $2.05B |
| 2026-04-30 | $2.18B |
| 2026-01-31 | $2.02B |
| 2025-10-31 | $2.02B |
| 2025-07-31 | $2.24B |
| 2025-04-30 | $2.09B |
| 2025-01-31 | $2.10B |
| 2024-10-31 | $2.15B |
| 2024-07-31 | $2.10B |
| 2024-04-30 | $1.91B |
| 2024-01-31 | $1.94B |
| 2023-10-31 | $1.70B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.